
EquitySector - HealthcareVery High Risk
Direct
NAV (23-Oct-26)
Returns (Since Inception)
Fund Size
₹1,078 Cr
Expense Ratio
1.07%
ISIN
INF209KB1O25
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
11 Jul 2019
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+7.96%
+5.90% (Cat Avg.)
3 Years
+19.08%
+19.10% (Cat Avg.)
5 Years
+13.40%
+13.28% (Cat Avg.)
Since Inception
+19.71%
— (Cat Avg.)
| Equity | ₹1,055.31 Cr | 97.94% |
| Others | ₹22.21 Cr | 2.06% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Torrent Pharmaceuticals Ltd | Equity | ₹99.97 Cr | 9.28% |
| Sun Pharmaceuticals Industries Ltd | Equity | ₹92.79 Cr | 8.61% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹69.35 Cr | 6.44% |
| Cipla Ltd | Equity | ₹68.71 Cr | 6.38% |
| Aurobindo Pharma Ltd | Equity | ₹48.7 Cr | 4.52% |
| Sai Life Sciences Ltd | Equity | ₹48.36 Cr | 4.49% |
| Ajanta Pharma Ltd | Equity | ₹46.82 Cr | 4.35% |
| Mankind Pharma Ltd | Equity | ₹38.95 Cr | 3.62% |
| Dr. Lal PathLabs Ltd | Equity | ₹37.77 Cr | 3.51% |
| Abbott India Ltd | Equity | ₹35.08 Cr | 3.26% |
| Emcure Pharmaceuticals Ltd | Equity | ₹34.54 Cr | 3.21% |
| Lupin Ltd | Equity | ₹31.71 Cr | 2.94% |
| Treps | Cash - Repurchase Agreement | ₹31.41 Cr | 2.92% |
| Ipca Laboratories Ltd | Equity | ₹29.2 Cr | 2.71% |
| Gland Pharma Ltd | Equity | ₹29.14 Cr | 2.70% |
| Fortis Healthcare Ltd | Equity | ₹26.1 Cr | 2.42% |
| Corona Remedies Ltd | Equity | ₹24.49 Cr | 2.27% |
| Divi's Laboratories Ltd | Equity | ₹24.16 Cr | 2.24% |
| Procter & Gamble Health Ltd | Equity | ₹19.58 Cr | 1.82% |
| Thyrocare Technologies Ltd | Equity | ₹18.94 Cr | 1.76% |
| Alkem Laboratories Ltd | Equity | ₹18.09 Cr | 1.68% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹16.66 Cr | 1.55% |
| Metropolis Healthcare Ltd | Equity | ₹15.91 Cr | 1.48% |
| Biocon Ltd | Equity | ₹15.63 Cr | 1.45% |
| Shilpa Medicare Ltd | Equity | ₹15.39 Cr | 1.43% |
| Piramal Pharma Ltd | Equity | ₹13.18 Cr | 1.22% |
| Dr Reddy's Laboratories Ltd | Equity | ₹12.2 Cr | 1.13% |
| Anthem Biosciences Ltd | Equity | ₹12.17 Cr | 1.13% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹12 Cr | 1.11% |
| Suraksha Diagnostic Ltd | Equity | ₹11.9 Cr | 1.10% |
| Manipal Health Enterprises Ltd | Equity | ₹11.5 Cr | 1.07% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹11.24 Cr | 1.04% |
| Pfizer Ltd | Equity | ₹10.87 Cr | 1.01% |
| Natco Pharma Ltd | Equity | ₹9.93 Cr | 0.92% |
| Net Receivable / Payable | Cash - Collateral | ₹-9.2 Cr | 0.85% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹8.97 Cr | 0.83% |
| Medi Assist Healthcare Services Ltd | Equity | ₹7.9 Cr | 0.73% |
| Vinati Organics Ltd | Equity | ₹7.47 Cr | 0.69% |
| Syngene International Ltd | Equity | ₹6.91 Cr | 0.64% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹6.51 Cr | 0.60% |
| Jubilant Pharmova Ltd | Equity | ₹6.49 Cr | 0.60% |
Large Cap Stocks
32.94%
Mid Cap Stocks
30.64%
Small Cap Stocks
33.29%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹1,047.83 Cr | 97.25% |
| Basic Materials | ₹7.47 Cr | 0.69% |
Standard Deviation
This fund
15.58%
Cat. avg.
16.41%
Lower the better
Sharpe Ratio
This fund
0.87
Cat. avg.
0.81
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.37
Higher the better
Since July 2019
ISIN INF209KB1O25 | Expense Ratio 1.07% | Exit Load 1.00% | Fund Size ₹1,078 Cr | Age 7 years 3 months | Lumpsum Minimum ₹1,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹4,53,154 Cr
Address
One World Centre, Tower 1, 17th Floor, Mumbai, 400 013
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments